Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Edoxaban

Edoxaban

Direct oral factor Xa inhibitor (DOAC)

DOACAFVTEAdult

Indication

NVAF β€’ VTE after initial parenteral therapy

At a glance

INDICATIONS (CORE USE)

NVAF (reduce dose if CrCl 15–50 or weight ≀60 kg); VTE after 5–10 days parenteral; **CrCl >95** AF reduced dose or excluded per label.

ADULT DOSE (STANDARD)

AF: 60 mg daily vs **30 mg** if CrCl 15–50 or weight ≀60 kg or interacting P-gp inducers; CrCl >95 β†’ **30 mg** or not recommended AF

MAX DOSE

60 mg daily usual max

Route

PO

PEDIATRIC DOSE

Not standard β€” specialist trials context

Do not miss

Must-not-miss safety points

Major warning

- **CrCl >95** in NVAF β†’ reduced efficacy signal β€” label mandates dose cap or avoidance - Must follow **parenteral lead-in** for VTE per label (5–10 days) - Strong inducers (rifampin etc.) β†’ reduced edoxaban exposure

Indications

USE IF: NVAF or VTE completion after parenteral phase when CrCl and weight fit label. AVOID IF: CrCl outside labeled range, pregnancy, mechanical mitral valve.

Primary

  • NVAF stroke prevention (with CrCl and dose ceiling rules)
  • VTE treatment after 5–10 days of parenteral anticoagulation

Dosing

STANDARD (ADULT PO)

60 mg once daily (AF) if CrCl >50 and not dose-reduction criteria

ADULT DOSE

Reduce to **30 mg daily** if CrCl **15–50**, weight **≀60 kg**, or specific P-gp inducers per label. **CrCl >95:** AF **30 mg** or contraindicated for AF in some labels β€” **verify**. VTE: 60 mg daily after heparin lead-in (or 30 mg if reduced criteria).

PEDIATRIC DOSE

N/A standard.

MAX DOSE

60 mg daily.

Practical Note

Once daily β€” easier adherence; still needs renal/weight checks.

Warnings

Clinical warnings

  • **Major active bleeding** or **high-risk bleeding** site β†’ do not initiate until addressed; hold if bleeding develops
  • **Duplicate anticoagulation** (DOAC + warfarin + LMWH + antiplatelet) β†’ medication reconciliation every transition β€” major bleed setup
  • **Mechanical heart valves** (especially mitral) / **moderate-severe mitral stenosis** / selected APS β†’ DOACs **contraindicated or not preferred** β€” use guideline-based therapy
  • **Pregnancy / breastfeeding** β†’ DOACs generally **avoided** in pregnancy; lactation β€” agent-specific β€” **specialist**
  • Neuraxial anesthesia
  • Premature discontinuation thrombotic risk

Adverse effects

  • Bleeding
  • anemia
  • rash
  • hepatic enzyme elevations (rare)

Contraindications

  • **Active pathological / major bleeding** β€” stabilize/reverse per protocol before routine (re)start unless embedded in explicit reversal plan
  • **Upcoming invasive procedure** β€” **do not continue blindly**; document **hold/bridge/switch** with anesthesia/surgery when applicable
  • **Mechanical mitral valve / moderate–severe mitral stenosis / selected APS** β€” **DOAC label restrictions** β€” use guideline-directed alternatives
  • Active bleeding
  • Hypersensitivity

Drug interactions

  • **Strong CYP3A4 + P-gp inhibitor** β†’ **avoid combination** or **switch agent** per label β€” do not rely on β€œmonitor only”
  • **Moderate inhibitor/inducer** β†’ **dose table per label** or **tighter bleed surveillance**
  • **NSAID or second antiplatelet added** β†’ **reassess** if surgery within days; else **clinical bleed monitoring**
  • Rifampin, St. John’s wort, carbamazepine β€” avoid (efficacy loss)
  • Verapamil, quinidine, dronedarone β€” dose reduction per label (P-gp)
  • Dual antiplatelet β†’ bleed

Special populations

Pediatrics

Not standard β€” specialist trials context

Pregnancy

**Pregnancy:** contraindicated. **

Lactation

** avoid.

Renal impairment

Central to dosing β€” all three CrCl bands + high CrCl ceiling. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + pharmacy / anticoagulation clinic):** - **CrCl >50** β†’ standard **60 mg daily** AF if not excluded by **weight ≀60 kg** or interacting inducers; **CrCl >95 mL/min** for AF β†’ **30 mg daily** or **not recommended** (reduced efficacy vs warfarin in trial) β€” **mandatory label read** - **CrCl 10–50** β†’ **30 mg daily** typical reduction band; **VTE** uses same renal cutoffs with **parenteral lead-in** β€” do not use AF table for VTE timing - **CrCl <15** / **<30** (product line) β†’ often **avoid** or not studied β€” **pharmacy**; accumulation increases bleed without predictable assay

Hepatic impairment

Moderate-severe hepatic impairment β€” avoid.

Elderly

Weight ≀60 kg triggers reduction.

Administration

PO with or without food; same time daily.

Monitoring

  • Monitor: - **What to check + when:** **CrCl** + **P-gp** interactors at start and when new drugs added β€” verify **CrCl >95 AF** band per label - **Escalation β€” bleeding:** **Hold**; **major** β†’ **4F-PCC** per protocol - **Escalation β€” VTE start:** **Parenteral lead-in** if label requires β€” do not skip - **Escalation β€” P-gp drug added:** Dose table **before** next dose - **Starting warfarin for acute VTE** β†’ **parenteral overlap** when indicated β€” **do not stop parenteral prematurely** per guideline - **Low-risk AF elective surgery** β†’ **avoid routine bridging** β€” use thromboembolic risk stratification
  • Recheck: - **Procedure or neuraxial in 48–72h** β†’ **reassess anticoagulant plan** β€” DOAC hold windows **β‰ ** warfarin; document last dose time - Baseline CrCl; recheck if volume depletion or AKI - **Interacting drug added or stopped** β†’ **recheck INR (warfarin) or reassess bleed risk / renal (DOAC)** within **48–72h** - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)
  • Hold if:
    - **Bleeding, unexplained Hb drop, thunderclap headache, or focal neuro signs** β†’ **hold** anticoagulant + escalate per bleed protocol

Overdose / toxicity

Clinical Picture

β€’ **No bleed:** Hold dose(s) β†’ recheck **renal function** + interactions β†’ resume per label β€’ **Minor bleed:** Hold DOAC β†’ local hemostasis + **CBC** β†’ restart per bleed resolution + pharmacy β€’ **Major bleed:** **DOAC reversal pathway** β€” **4F-PCC** Β± **andexanet** (per label/protocol) + **ICU** + source control + hematology

Immediate Actions

β€’ **No bleed:** Hold β†’ hemodynamic check β†’ recheck labs/meds β†’ **no vitamin K** for anticoagulant effect β€’ **Minor bleed:** Hold β†’ pressure/packing β†’ **CBC** β†’ observe per site risk β€’ **Major bleed:** Stop DOAC β†’ ABCs β†’ type & screen β†’ **call reversal protocol** (**PCC / andexanet**) β†’ **ICU**

Antidote

**Targeted reversal agents:** **Andexanet** (where indicated) and/or **4F-PCC** per protocol β€” **vitamin K does not reverse DOAC** anticoagulation

Decontamination

β€’ **Toxic ingestion (early):** Charcoal if airway protected β€’ **Bleeding patient:** Management by **hemorrhage severity**, not decontamination alone

Escalation

β€’ **Major:** **ICU**; IR/surgery; **PCC/andexanet** per protocol β€’ **Minor:** Observe if high-risk bleed site

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Once-daily** DOAC. β†’ **High CrCl (>95)** AF rule is unique β€” memorize for boards. β†’ VTE needs **heparin first**.

Clinical pearls

Compare 30 mg triggers (weight, CrCl, drugs) vs apixaban 2.5 mg criteria β€” different logic. *Anticoagulation (all agents):* **A/B/C bleed tiers** β€” no bleed (hold/adjust) vs minor (hold/protocol) vs major (reversal + ICU/heme). **Warfarin:** high INR without bleed **β‰ ** major-bleed pathway; **PCC + IV K** for life-threatening bleed. **Bridging:** warfarin **slow on/off**; **parenteral overlap** when indicated for acute VTE; **no routine bridge** low-risk AF; **DOAC↔warfarin** table-specific. **Neuraxial:** explicit **last-dose β†’ procedure** documentation. Never extend therapy without indication review.

Anticoagulant safety

  • CrCl ceiling AF
  • Weight 60 kg cutoff
  • VTE lead-in

Pharmacokinetics

Renal elimination ~50%; TΒ½ ~10–14 h; minimal CYP metabolism.

Mechanism of action

Selective factor Xa inhibitor.

Common brand names

Saudi Arabia

Lixiana, Savaysa

Global

(placeholder β€” verify local prefilled syringe / vial)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Reversal agents (PCC, andexanet, idarucizumab) availability and dosing vary by hospital β€” follow local protocol.
  • Perioperative interruption and bridging are **indication-specific** β€” do not copy warfarin rules onto DOACs blindly.
  • Switching between anticoagulants requires manufacturer tables + pharmacy to avoid under- or over-anticoagulation.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary
  • CHEST / ACCP antithrombotic guidance (indication-specific)
  • ESC / AHA stroke and anticoagulation guidelines where applicable
  • ASH β€” HIT and VTE resources
  • FDA / SFDA product labeling
  • Institutional anticoagulation service / formulary

Do not miss

  • Document indication, target intensity, and planned duration in the chart
  • Reassess renal/hepatic function after AKI, dehydration, or new interacting medications
  • **CrCl >95 AF band:** Reduced dose or avoid β€” **efficacy** concern in label, not optional fine print.
  • **VTE:** Requires **parenteral lead-in** per label β€” do not start edoxaban day 0 alone if contraindicated.
  • **Reversal:** **4F-PCC** pathway β€” not vitamin K for anticoagulant reversal.
  • **Interactions:** P-gp modulators β†’ dose reduction table before prescribing.
  • Starting edoxaban for acute VTE **without** parenteral lead-in β†’ wrong if label requires overlap.
  • **Bridging & transitions (factory scaffold):**
  • **Warfarin** has **delayed onset/offset** β€” do not expect immediate effect or rapid washout like DOACs.
  • **Acute thrombosis** may require **parenteral overlap** when starting/overlapping warfarin or per label β€” **indication-specific**.
  • **Low-risk AF peri-procedure:** **do NOT routinely bridge** β€” stratify thromboembolic risk per guideline/CHEST-style tables.
  • **DOAC ↔ warfarin** switches are **indication- and table-specific** β€” pharmacy + label (valve, APS, renal).
  • **Neuraxial / high-bleed procedure:** document **last dose**, **ASRA/institutional** windows, **restart** only when hemostasis secure.
  • CrCl ceiling AF
  • Weight 60 kg cutoff
  • VTE lead-in